In vitro activities of the novel cephalosporin LB 11058 against multidrug-resistant staphylococci and streptococci

In vitro activities of the novel cephalosporin LB 11058 against multidrug-resistant staphylococci and streptococci

Author Sader, Helio S. Autor UNIFESP Google Scholar
Johnson, D. M. Google Scholar
Jones, R. N. Google Scholar
Institution JONES Grp JMI Labs
Universidade Federal de São Paulo (UNIFESP)
Tufts Univ
Abstract LB 11058 is a novel parenteral cephalosporin with a C-3 pyrimidinyl-substituted vinyl sulfide group and a C-7 2-amino-5-chloro-1,3-thiazole group. This study evaluated the in vitro activity and spectrum of LB 11058 against 1,245 recent clinical isolates, including a subset of gram-positive strains with specific resistant phenotypes. LB 11058 was very active against Streptococcus pneumoniae. the novel cephalosporin was 8- to 16-fold more potent than ceftriaxone, cefepime, or amoxicillin-clavulanate against both penicillin-intermediate and -resistant S. pneumoniae. LB 11058 was also very active against both beta-hemolytic streptococci (MIC at which 90% of isolates were inhibited [MIC90], less than or equal to0.008 mug/ml) and viridans group streptococci (MIC90, 0.03 to 0.5 mug/ml), including penicillin-resistant strains. Among oxacillin-susceptible Staphylococcus aureus, LB 11058 MIC results varied from 0.06 to 0.25 mug/ml (MIC50, 0.12 mug/ml), while among oxacillin-resistant strains LB 11058 MICs varied from 0.25 to 1 mug/ml (MIC50, 1 mug/ml). Coagulase-negative staphylococci showed an LB 11058 susceptibility pattern similar to that of S. aureus, with all isolates being inhibited at less than or equal to1 mug/ml. LB 11058 also showed reasonable in vitro activity against Enterococcus faecalis, including vancomycin-resistant strains (MIC50, 1 mug/ml), and Bacillus spp. (MIC50, 0.25 mug/ml); however, it was less active against Enterococcus faecium (MIC50, >64 mug/ml) and Corynebacterium spp. (MIC50, 32 mug/ml). Against gram-negative pathogens, LB 11058 showed activity against Haemophilus influenzae (MIC90, 0.25 to 0.5 mug/ml) and Moraxella catarrhalis (MIC90, 0.25 mug/ml), with MICs not influenced by beta-lactamase production. in conclusion, LB 11058 demonstrated a broad antibacterial spectrum and was highly active against gram-positive bacteria, particularly against multidrug-resistant staphylococci and streptococci.
Language English
Date 2004-01-01
Published in Antimicrobial Agents and Chemotherapy. Washington: Amer Soc Microbiology, v. 48, n. 1, p. 53-62, 2004.
ISSN 0066-4804 (Sherpa/Romeo, impact factor)
Publisher Amer Soc Microbiology
Extent 53-62
Access rights Open access Open Access
Type Article
Web of Science ID WOS:000187728500007

Show full item record


Name: WOS000187728500007.pdf
Size: 84.32Kb
Format: PDF
Open file

This item appears in the following Collection(s)




My Account